with nearly 50% driven by KRAS-G12D. Small molecules to target mutant KRAS have long eluded researchers because its notoriously smooth surface makes it challenging to identify pockets for a drug ...

Unfortunately, KRAS is largely devoid of pockets and crevices in which a therapeutic molecule can nestle, so most of its mutated forms — including the most prevalent, a variant called G12D (in ...

近日，来自美国洛克菲勒大学的Kıvanç Birsoy研究小组在Nature杂志上发表题为Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer的研究论文 ...

近期，一篇题为《衰老生物标志物验证》的综述文章发表于专注生化与分子生物学领域的顶尖期刊Nature Medicine，并入选“精选文章”。研究由来自 ...

这种单一分子可以将17种最常见的KRAS突变体中的13种失活，包括癌症最常见的KRAS G12D (D，天冬氨酸)，并且可能有助于确定抑制或降解KRAS是否具有更好的治疗效果。 KRAS G12C 抑制剂的发展促进了人们努力寻找新的KRAS抑制剂，特别是靶向KRAS G12D 的抑制剂。目前 ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) ...

A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

研究团队成功地将 KRAS、PROTAC 和 VHL 三种成分共晶体化。利用 X 射线晶体学，他们可以直观地看到这种复合物的原子细节结构，帮助他们了解这种小 ...

AST2169是公司自主研发的具有全球知识产权的KRAS G12D选择性抑制剂。KRAS G12D突变是KRAS突变的一种常见的亚型，存在于非小细胞肺癌、结直肠癌、胰腺 ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other ...

Nature Medicine is an academic journal publishing research articles, reviews, news and commentaries in the biomedical area, including both basic research and early-phase clinical research.

每经AI快讯，加科思公告，公司自主研发的Pan-KRAS抑制剂AB-23E73的新药临床试验申请已经获得国家药品监督管理局药品审评中心批准。此前，美国的IND ...